Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 3,387 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: TPX-0005, Metformin Hydrochloride, Digoxin, Rosuvastatin Calcium; Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Canton, Ohio

Conditions: Neoplasms, Tumor
Interventions: IMC-TR1; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
Interventions: PRTH-101, Pembrolizumab; Biological
Lead sponsor: Incendia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • St Louis, Missouri

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Interventions: IPN01194; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions: M1069; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Hackensack, New Jersey • Nashville, Tennessee

Conditions: Advanced Cancer, Cervical Cancer
Interventions: AGEN2034; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more

Conditions: Solid Tumors Harboring a BRAF V600 Mutation
Interventions: LGX818, MEK162, LEE011; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 6
States / cities: Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Medullary Thyroid Carcinoma
Interventions: Bortezomib, Vandetanib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Renal Cell Carcinoma
Interventions: IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 24
States / cities: Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions: LMB-100, Tofacitinib, Mesothelin Expression; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor
Interventions: OBI-992; Drug
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Glendale, California • La Jolla, California • Detroit, Michigan + 3 more

Conditions: Solid Tumors
Interventions: LY573636-sodium, Liposomal Doxorubicin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Scottsdale, Arizona • Encinitas, California • Oklahoma City, Oklahoma + 2 more

Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
Interventions: PF-08046052; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Los Angeles, California • Santa Monica, California • Tampa, Florida + 10 more

Conditions: Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions: XRD-0394, Palliative radiotherapy; Drug · Radiation
Lead sponsor: XRad Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Conditions: Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
Interventions: GEN1107; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Tumors, Lymphoma
Interventions: Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma; Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • Omaha, Nebraska • San Antonio, Texas

Conditions: Advanced Solid Tumors
Interventions: Treatment with ARQ 197 in combination with gemcitabine; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more

Conditions: Solid Tumor, Advanced Solid Tumor
Interventions: M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 8
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more

Conditions: Malignant Solid Tumor
Interventions: I-124 PGN650 for PET/CT; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumor
Interventions: BBI-825; Drug
Lead sponsor: Boundless Bio, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Santa Monica, California • Grand Rapids, Michigan • New York, New York + 2 more

Conditions: Selected Advanced Solid Tumors
Interventions: MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more

Search by objective public record fields.

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

First in Human Study of M1069 in Advanced Solid Tumors

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

PRO1107 in Patients With Advanced Solid Tumors

A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors